| Name | Title | Contact Details |
|---|
Atosa is a major manufacturer of commercial kitchen equipment, with a breadth of offering including refrigeration, cooking equipment, warming/holding equipment, stainless steel fabrication equipment, and much more. Atosas world-class manufacturing facilities and highly skilled employees, combined with innovative manufacturing procedures ensure that our customers always receive top-quality products at economical prices.
Delinea is an ISO 9001:2015 certified CNC manufacturing company which specializes in 3+2 positional and 3 axis precision milling. Founded in 2019 by Vincent and Dan Krische, Delinea is based out of a 4,800 square foot facility in Loveland Colorado. Featuring state-of-the-art equipment and automated software we provide the crucial digital manufacturing service that you need in order to become top of your industry and a leader in innovation.
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
The Big Biscuit, founded in 2000, is an All-American breakfast and lunch concept focusing on freshly prepared classic comfort food consistently served with generous portions in a family-friendly environment. The Big Biscuit has 27+ locations in Kansas, Missouri, Oklahoma, and Arkansas
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.